Updated On: 19 November, 2020 02:35 PM IST | London | IANS
We were pleased to see that our vaccine was not only well-tolerated in older adults, but also stimulated similar immune responses to those seen in younger volunteers, said Dr Maheshi Ramasamy, an investigator at the Oxford Vaccine Group

Photo for representational purpose
COVID-19 vaccine being developed by British-Swedish pharmaceutical firm AstraZeneca and Oxford University produced a strong immune response in older adults, raising hopes that it can protect the age groups most at risk from the virus.
The study, published in The Lancet medical journal, suggest that those aged over 70 -- who are at higher risk of serious illness and death from COVID-19 -- could build robust immunity to the novel coronavirus.